Global Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Targeted Drugs for Breast Cancer Market Overview

• 1.1 Product Overview and Scope of Targeted Drugs for Breast Cancer
• 1.2 Classification of Targeted Drugs for Breast Cancer by Types
  • 1.2.1 Global Targeted Drugs for Breast Cancer Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Targeted Drugs for Breast Cancer Revenue Market Share by Types in 2018
  • 1.2.3 HER-2 Targeted Drugs
  • 1.2.4 CDK4/6 Inhibitors
  • 1.2.5 PARP Targeted Drugs
  • 1.2.6 PI3K/AKT/mTor Pathway Inhibitors
  • 1.2.7 ER Targeted Drugs
  • 1.2.8 Aromatase Inhibitors
  • 1.2.9 Tubulin Inhibitors
  • 1.2.10 VEGF Targeted Drugs
  • 1.2.11 YTMS Targeted Drugs
  • 1.2.12 Other
• 1.3 Global Targeted Drugs for Breast Cancer Market by Application
  • 1.3.1 Global Targeted Drugs for Breast Cancer Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Drug Center
  • 1.3.5 Other
• 1.4 Global Targeted Drugs for Breast Cancer Market by Regions
  • 1.4.1 Global Targeted Drugs for Breast Cancer Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
• 1.5 Global Market Size of Targeted Drugs for Breast Cancer (2014-2024)

2 Manufacturers Profiles

• 2.1 Roche
  • 2.1.1 Business Overview
  • 2.1.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Roche Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Teva
  • 2.2.1 Business Overview
  • 2.2.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Teva Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Mylan
  • 2.3.1 Business Overview
  • 2.3.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Mylan Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Hikma
  • 2.4.1 Business Overview
  • 2.4.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Hikma Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Hengrui Medicine
  • 2.5.1 Business Overview
  • 2.5.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Hengrui Medicine Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Cipla
  • 2.6.1 Business Overview
  • 2.6.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Cipla Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Reliance Group
  • 2.7.1 Business Overview
  • 2.7.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Reliance Group Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Hetero
  • 2.8.1 Business Overview
  • 2.8.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Hetero Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Pfizer
  • 2.9.1 Business Overview
  • 2.9.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Pfizer Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Eli Lilly
  • 2.10.1 Business Overview
  • 2.10.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Eli Lilly Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Novartis
  • 2.11.1 Business Overview
  • 2.11.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Novartis Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 CANbridge
  • 2.12.1 Business Overview
  • 2.12.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 CANbridge Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Puma Biotechnology
  • 2.13.1 Business Overview
  • 2.13.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Puma Biotechnology Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 AstraZeneca
  • 2.14.1 Business Overview
  • 2.14.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 AstraZeneca Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Chugai Pharmaceutical
  • 2.15.1 Business Overview
  • 2.15.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Eisai
  • 2.16.1 Business Overview
  • 2.16.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Eisai Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 GlaxoSmithKline
  • 2.17.1 Business Overview
  • 2.17.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 GlaxoSmithKline Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Bristol-Myers Squibb
  • 2.18.1 Business Overview
  • 2.18.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 Otsuka Pharmaceutical
  • 2.19.1 Business Overview
  • 2.19.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.20 Merck
  • 2.20.1 Business Overview
  • 2.20.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.20.2.1 Product A
    • 2.20.2.2 Product B
  • 2.20.3 Merck Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.21 BioMarin
  • 2.21.1 Business Overview
  • 2.2.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.21.2.1 Product A
    • 2.21.2.2 Product B
  • 2.21.3 BioMarin Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.22 Hengrui Pharmaceutical
  • 2.22.1 Business Overview
  • 2.22.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.22.2.1 Product A
    • 2.22.2.2 Product B
  • 2.22.3 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.23 Beijing Biostar Technologies
  • 2.23.1 Business Overview
  • 2.23.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.23.2.1 Product A
    • 2.23.2.2 Product B
  • 2.23.3 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.24 Bayer
  • 2.24.1 Business Overview
  • 2.24.2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.24.2.1 Product A
    • 2.24.2.2 Product B
  • 2.24.3 Bayer Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

3 Global Targeted Drugs for Breast Cancer Market Competition, by Players

• 3.1 Global Targeted Drugs for Breast Cancer Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Targeted Drugs for Breast Cancer Players Market Share
  • 3.2.2 Top 10 Targeted Drugs for Breast Cancer Players Market Share
• 3.3 Market Competition Trend

4 Global Targeted Drugs for Breast Cancer Market Size by Regions

• 4.1 Global Targeted Drugs for Breast Cancer Revenue and Market Share by Regions
• 4.2 North America Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.3 Europe Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.5 South America Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

5 North America Targeted Drugs for Breast Cancer Revenue by Countries

• 5.1 North America Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 5.2 USA Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 5.3 Canada Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

6 Europe Targeted Drugs for Breast Cancer Revenue by Countries

• 6.1 Europe Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 6.2 Germany Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.3 UK Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.4 France Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.5 Russia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.6 Italy Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Countries

• 7.1 Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 7.2 China Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.3 Japan Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.4 Korea Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.5 India Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

8 South America Targeted Drugs for Breast Cancer Revenue by Countries

• 8.1 South America Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 8.2 Brazil Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Targeted Drugs for Breast Cancer by Countries

• 9.1 Middle East and Africa Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.3 UAE Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

10 Global Targeted Drugs for Breast Cancer Market Segment by Type

• 10.1 Global Targeted Drugs for Breast Cancer Revenue and Market Share by Type (2014-2019)
• 10.2 Global Targeted Drugs for Breast Cancer Market Forecast by Type (2019-2024)
• 10.3 HER-2 Targeted Drugs Revenue Growth Rate (2014-2024)
• 10.4 CDK4/6 Inhibitors Revenue Growth Rate (2014-2024)
• 10.5 PARP Targeted Drugs Revenue Growth Rate (2014-2024)
• 10.6 PI3K/AKT/mTor Pathway Inhibitors Revenue Growth Rate (2014-2024)
• 10.7 ER Targeted Drugs Revenue Growth Rate (2014-2024)
• 10.8 Aromatase Inhibitors Revenue Growth Rate (2014-2024)
• 10.9 Tubulin Inhibitors Revenue Growth Rate (2014-2024)
• 10.10 VEGF Targeted Drugs Revenue Growth Rate (2014-2024)
• 10.11 YTMS Targeted Drugs Revenue Growth Rate (2014-2024)
• 10.12 Other Revenue Growth Rate (2014-2024)

11 Global Targeted Drugs for Breast Cancer Market Segment by Application

• 11.1 Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2014-2019)
• 11.2 Targeted Drugs for Breast Cancer Market Forecast by Application (2019-2024)
• 11.3 Hospital Revenue Growth (2014-2019)
• 11.4 Clinic Revenue Growth (2014-2019)
• 11.5 Drug Center Revenue Growth (2014-2019)
• 11.6 Other Revenue Growth (2014-2019)

12 Global Targeted Drugs for Breast Cancer Market Size Forecast (2019-2024)

• 12.1 Global Targeted Drugs for Breast Cancer Market Size Forecast (2019-2024)
• 12.2 Global Targeted Drugs for Breast Cancer Market Forecast by Regions (2019-2024)
• 12.3 North America Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.4 Europe Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.6 South America Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology